Medical Therapeutics

Resvita Biosciences

Brief Description

Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.

Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced...

AsparaGlue

Brief Description

AsparaGlue has developed a superglue-like medical adhesive for external wound closure and internal tissue adhesion. The proprietary technology is the world’s only biocompatible and biodegradable medical superglue.

Inventors

Philip Messersmith, Subhajit Pal, Ji Soo Shin, Kelsey Gray DeFrates

Company Founders

UC Berkeley Professor Phillip Messersmith (Ph.D., Professor of Bioengineering and Materials Science & Engineering) and Subhajit Pal (postdoc, 2022-present, Messersmith Lab)

Timeline 2023. Company founded; joins Berkeley Skydeck...

BreezeBio

Brief Description

BreezeBio develops innovative therapies through targeted delivery of genetic medicines. The company's founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe and effective medicines for genetic diseases.

The company's proprietary Polymer nanoparticle can deliver CRISPR protein and gRNA. CRISPR in a protein form has many advantages, delivery has been a challenge limiting its application. To deliver CRISPR protein, encapsulation of CRISPR ribonucleoprotein...

Inapill

Brief Description

Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.

The company was co-founded by Greg Timblin and Josh Farahzad. CEO Timblin earned his Ph.D. in Molecular & Cell Biology from UC Berkeley in 2014, in the labs of Professors Mark Schlissel and Robert Tjian. He also served as a postdoctoral fellow in Professor Kaoru Saijo’s lab at UC Berkeley, and then in Professor Val Weaver’s lab at UCSF.

Inventors

Kaoru Saijo, Greg Timblin...

Stylus Medicine

Brief Description

Stylus Medicine has created a new gene editing technology based on viral proteins called recombinases. These proteins naturally insert large swaths of DNA into bacterial genomes, but Stylus used machine learning to design recombinases that target specific regions of the human genome. The method is based on the pioneering work of Patrick Hsu, UC Berkeley assistant professor of bioengineering and co-founder and a core investigator of the Arc Institute. The company is on a mission to develop next-generation therapies for disease through genome engineering and chromatin...

EditPep, Inc.

Brief Description

CRISPR therapies enabled by a simple, potent delivery platform. The biotechnology company creates a class of peptides capable of delivering CRISPR enzymes into clinically-relevant and previously untransfectable cell types, enabling clients to get CRISPR therapies.

Inventors

Ross Wilson, Dana Foss, Alexander Marson, Srishti Sahu, David-Huy Nguyen, John Hunsinger, Daniel Carr

Company Founders

Dana Foss (UC Berkeley postdoc 2017-2022), UC Berkeley Assistant Adjunct Professor of Molecular Therapeutics Ross Wilson

Timeline 2021...

QSX Bio

Brief Description

Developing medical therapeutics and vaccines through biosynthesis of natural compounds in plants.

Inventors

Jay Keasling, Yuzhong Liu, Henrik Scheller, Xiaoyue Chen, Samantha Aiko Crowe, James Reed, Laetitia Martin, Graham Arthur Hudson, Fei Gan

Company Founders

Yuzhong Liu

Timeline 2025. Company founded

Vivere Oncotherapies

Brief Description

Gene and cell therapies for cancer.

Inventors

Adam Schieferecke, John Dueber, David Schaffer, Juan Eduardo Hurtado, Hyun-Cheol Lee

Company Founders

Wanichaya Noiwangklang, Adam Schieferecke (UC Berkeley, Ph.D., Doctor of Philosophy, Mollecular and Cellular Biology), Juan Hurtado, Hyuncheol Lee, David Schaffer, John Dueber

Timeline 2024. Company founded.

Avista Therapeutics

Brief Description

Avista Therapeutics develops innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on quality of life. The company leverage a computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors. A quantitative, in vivo-based approach and clinical ophthalmology expertise allows Avista Therapeutics to rapidly translate new gene therapies to the clinic.

Inventors

Stephen Graf Brohawn, Hillel Adesnik, Madeline McCloud

Company Founders

Leah Byrne (UC Berkeley PhD, 2007...

DNA Nanobots, LLC

Brief Description

DNA Nanobots is focused on developing the next generation of targeted nanomedicines and reshaping gene therapy by delivering genes previously considered undeliverable. Utilizing precise DNA self-assembly (DNA origami), the company engineers nanobots designed to carry and release therapeutic payloads directly to diseased cells with unprecedented specificity, minimizing systemic toxicity, and maximizing treatment efficacy.

Inventors

Jennifer Doudna, Enrique Lin Shiao, Rachael Lew

Company Founders

Patrick Halley, Christopher Lucas, Carlos Castro, Adel Mikhail...